PRO-BOOST-LC: Whole-Gland Boost Strategies Versus SBRT Monotherapy in PSMA-Staged Localized and Locally Advanced Prostate Cancer

PRO-BOOST-LC is a prospective, multicenter, randomized phase II/III clinical trial for men with localized or locally advanced prostate cancer without lymph node or distant metastases, confirmed using prostate-specific membrane antigen positron emission tomography/computed tomography (PSMA PET/CT). Radiotherapy is an established curative treatment option for prostate cancer. Several modern radiotherapy strategies can safely deliver high radiation doses to the prostate while limiting dose to surrounding organs. These include stereotactic body radiotherapy (SBRT), high-dose-rate (HDR) brachyther

Trial Details

NCT ID
NCT07426055
Phase
PHASE2 / PHASE3
Sponsor
Affidea Nu-med Center of Oncological DIagnostics and Therapy
Status
RECRUITING
Cancer Type
Prostate Cancer
Interventions
  • Stereotactic Body Radiotherapy (SBRT) Monotherapy
  • External Beam Radiotherapy (EBRT) Backbone
  • High-Dose-Rate Brachytherapy Boost
  • Low-Dose-Rate Brachytherapy Boost
  • Stereotactic Body Radiotherapy (SBRT) Boost
  • Androgen Deprivation Therapy (ADT)
Locations (sample)
  • Zamość, Lublin Voivodeship, Poland|50.72314,23.25196

Key Eligibility Criteria

  • Male patients aged ≥18 years.
  • Histologically confirmed adenocarcinoma of the prostate.
  • Localized or locally advanced prostate cancer classified as cT1-4, cN0, cM0.
  • Negative pelvic nodal and distant metastatic disease on baseline PSMA PET.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Prostate Cancer Trials on Trialify →